Interleukin Genetics, Inc. (Interleukin Genetics) has entered into an agreement with Amway Global. With this agreement, Amway Global Independent Business Owners will be able to sell Interleukin Genetics' Inherent Health brand of genetic tests, including the new Weight Management Genetic Test.
Interleukin will fulfill and process all Inherent Health genetic tests through the company’s CLIA-certified laboratory in Waltham, Massachusetts. Amway Global will assist with marketing, implementation and technical operations related to the sales of genetic tests sold through its organization.
The Inherent Health suite of genetic tests that Amway Global will now carry includes:
Weight Management Genetic Test that provides new information beyond traditional assessments to help individuals understand the genetic factors that result in better weight management. The test product determines whether an individual is likely to benefit more from a low fat, low carbohydrate or balanced calorie reduced diet, and whether an individual is likely to obtain greater benefit from normal or more vigorous exercise to most efficiently lose weight based on their genotype.
Heart Health Genetic Test that identifies a person’s genetic predisposition for a certain type of heart disease. The genetic analysis identifies variations in the IL1 gene, which is associated with inflammation. Excess inflammation has been implicated as a significant risk factor for heart disease.
Nutritional Needs Genetic Test that identifies DNA variations in genes crucial to B-vitamin metabolism and the ability to manage oxidative stress. Individuals that show suboptimal results for the genes can be at increased risk for ineffective utilization of B-vitamins and potential for cell damage caused by oxidative stress.
Bone Health Genetic Test identifies whether an individual is more likely to be susceptible to spine fractures and low bone mineral density associated with osteoporosis. This new test is expected to be available by the end of 2009.